Pegcetacoplan Extension Study Update

Jeffrey S. Heier, MD

Show Description +

Jeffrey S. Heier, MD, explains 1-year data from the GALE extension study of pegcetacoplan (Syfovre, Apellis), which showed a continued increase in the treatment effect with 3 years of treatment.

Posted: 11/08/2023

Keywords:

retina-meeting-recap

•

GALE

•

Syfovre

•

Apellis

•

Clinical Trials

•

Geographic Atrophy (GA)

•

Retina Subspecialty Day

Up Next

Name: Pegcetacoplan Extension Study Update
Uploaded: 2023-11-08T21:53:13+00:00
Description: Jeffrey S. Heier, MD, explains 1-year data from the GALE extension study of pegcetacoplan (Syfovre, Apellis), which showed a continued increase in the treatment effect with 3 years of treatment.

Two Years of Treatment with Avacincaptad Pegol

Arshad M. Khanani, MD, MA

Efficacy of Faricimab with PEDs Revealed

Jennifer I. Lim, MD

Genetics: Now or Later

Inas Aboobakar, MD

New Glaucoma Devices in the Pipeline

Matt Schlenker, MD

Virtual Visual Fields: Are They Ready for Prime Time?

Steven R. Sarkisian Jr, MD

Cutting-Edge Translational Research From the Next Generation

Jodhbir Singh Mehta, MD, PhD

Visual Outcomes With a Small-Aperture IOL in Post-Radial Keratotomy Patients

Sudhinder Koushik, MD

Drug-Eluting IOLs

Kenneth Mandell, MD, PhD

Pearls for Subretinal Gene Therapy

Christina Y. Weng, MD, MBA

A CRISPR Gene Editing Update

Glenn Yiu, MD, PhD

A New Approach to Combatting Blindness in RP

Russell N. Van Gelder, MD, PhD

Tackling TRDs with Limited Membranectomy

John W. Kitchens, MD

Working Toward Diversity in Retina Clinical Trials

Adrienne W. Scott, MD

Diversity in Ocular Oncology

Basil K. Williams Jr, MD

The Latest in Retina Surgical Instrumentation

David R. Chow, MD

Update on Glaucoma Lasers

Aaki Shukla, MD, and Mary Qiu, MD

Impact of 6-Week Treatment With Lotilaner Ophthalmic Solution, 0.25% on Eyes With Severe Demodex Blepharitis

Mitchell Shultz, MD

Walking Over a Flat Earth: A Jump Toward Diversity, Equity, and Inclusion (DEI)

Basil Williams, MD

$Rethinking Refractive Surgery: What’s New In 2023?$

Rethinking Refractive Surgery: What’s New In 2023?

George O. Waring IV, MD, FACS

Intracameral Low Molecular Weight Heparin for DMEK: A Pilot Safety Study

Rahul Tonk, MD, MBA

Combination Therapy in the Treatment of Dry Eye vs. Traditional Cyclosporine

John A. Hovanesian, MD

Wet AMD Gene Therapy at 3 Years: Ixo-vec

Carl D. Regillo, MD, FACS

Back to All Videos

Pegcetacoplan Extension Study Update

Jeffrey S. Heier, MD

Jeffrey S. Heier, MD, explains 1-year data from the GALE extension study of pegcetacoplan (Syfovre, Apellis), which showed a continued increase in the treatment effect with 3 years of treatment.

Posted: 11/08/2023

Keywords:

retina-meeting-recap

•

GALE

•

Syfovre

•

Apellis

•

Clinical Trials

•

Geographic Atrophy (GA)

•

Retina Subspecialty Day

Please log in to leave a comment.

Meeting Coverage:

American Academy of Ophthalmology

Pegcetacoplan Extension Study Update

Up Next

Pegcetacoplan Extension Study Update

More From AAO: 2023 Coverage